Jade Biosciences, Inc. 8-K

What Happened

• Jade Biosciences, Inc. (JBIO) filed an 8-K reporting governance changes approved at its 2026 Annual Meeting held June 9, 2026. Stockholders approved an amendment to the Company’s Articles of Incorporation to waive jury trials in certain circumstances; that amendment was added as Article X and became effective when the Amended and Restated Articles were filed with the Nevada Secretary of State on June 10, 2026.
• Separately, the Board approved Amended and Restated Bylaws on June 8, 2026, which became effective June 9, 2026. The bylaws include technical, modernizing and clarifying changes to align with the Nevada Revised Statutes.

Key Details

• Stockholder vote: amendment to Articles (jury trial waiver) approved at the June 9, 2026 Annual Meeting.
• Filing/effective dates: Amended and Restated Bylaws effective June 9, 2026; Amended and Restated Articles (including Article X) filed June 10, 2026.
• Bylaw changes include removal of the prior requirement to prepare and make available a ten-day pre-meeting stockholder list, explicit authorization for virtual/remote stockholder and Board meetings, and clarified record-date rules for postponed meetings.
• Voting standard updated for non-director matters to “number of votes cast in favor … exceeds the number of votes cast in opposition” (language aligned with NRS).

Why It Matters

• These are governance and procedural changes—not financial transactions or leadership changes—and may affect how shareholder meetings are run and how certain disputes are resolved (the jury-trial waiver alters the forum/process for some claims).
• The bylaws modernization (virtual meetings, record-date clarity, voting standard update) may change logistics and voting outcomes for future stockholder actions.
• Investors who want the exact language and potential legal impact should review the Amended and Restated Articles and Bylaws filed as exhibits to the 8-K.